MAIA Biotechnology, Inc. (MAIA)

US — Healthcare Sector
Peers: LCTX  ARMP  FREQ  PRTG  AGE  LRMR  GRPH  LYRA  GNLX  CMRA  DYAI  CING  MNPR  TRGNF  EPRXF  CSBR  LUMO  ROIVW  FTHWF  TLPPF  NAUT 

Automate Your Wheel Strategy on MAIA

With Tiblio's Option Bot, you can configure your own wheel strategy including MAIA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MAIA
  • Rev/Share 0.0
  • Book/Share 0.1785
  • PB 9.7505
  • Debt/Equity 0.0
  • CurrentRatio 2.3454
  • ROIC -2.708

 

  • MktCap 52734726.0
  • FreeCF/Share -0.5892
  • PFCF -3.2313
  • PE -2.4457
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -5.9006

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
MAIA
Published: June 18, 2025 by: Business Wire
Sentiment: Neutral

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies.

Read More
image for news MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
MAIA
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial.

Read More
image for news MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
MAIA
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer.

Read More
image for news MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
MAIA
Published: May 15, 2025 by: Business Wire
Sentiment: Neutral

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.

Read More
image for news MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Best Momentum Stocks to Buy for May 6th
BYRN, MAIA, OCX
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive

MAIA, BYRN and OCX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 6, 2025.

Read More
image for news Best Momentum Stocks to Buy for May 6th
New Strong Buy Stocks for May 6th
BBVA, BYRN, HMY, MAIA, OCX
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive

MAIA, BYRN, OCX, BBVA and HMY have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2025.

Read More
image for news New Strong Buy Stocks for May 6th
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
MAIA
Published: May 05, 2025 by: Business Wire
Sentiment: Neutral

CHICAGO--(BUSINESS WIRE)--CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement.

Read More
image for news CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know
MAIA
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive

MAIA Biotechnology, Inc. (MAIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
MAIA
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025.

Read More
image for news MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
MAIA
Published: February 24, 2025 by: Business Wire
Sentiment: Neutral

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million.

Read More
image for news MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
MAIA Biotechnology Announces Private Placement of $2,715,000
MAIA
Published: February 18, 2025 by: Business Wire
Sentiment: Neutral

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of $2,715,000.

Read More
image for news MAIA Biotechnology Announces Private Placement of $2,715,000

About MAIA Biotechnology, Inc. (MAIA)

  • IPO Date 2022-07-28
  • Website https://www.MAIABiotech.com
  • Industry Biotechnology
  • CEO Vlad Vitoc
  • Employees 13
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.